Cepheid (CPHD) Reports Q4 EPS of 7c, Offers FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leerink Partners Reiterates Market Perform on Cepheid (CPHD) Following 4Q
February 3, 2016 8:51 AM ESTLeerink Partners reiterated a Market Perform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $33.00 (from $39.00), following the company's 4Q earnings report. CPHDs reported revenue of $147M was in-line with the Street's forecast of $147M. Higher-than-consensus clinical systems sales were offset... More
